|Synonyms||DT-1687; PXT-002331; PXT-2331|
|Chemical and physical data|
|Molar mass||421.515 g/mol g·mol−1|
|3D model (JSmol)|
Foliglurax (developmental code names PXT-002331, DT-1687) is a positive allosteric modulator of the metabotropic glutamate receptor 4 (mGluR4) which is under development by Prexton Therapeutics for the treatment of Parkinson's disease. As of July 2017, it is in phase II clinical trials.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|